Intralesional Bevacizumab Injection on Primary Pterygium (bevacizumab)

Khon Kaen University

Status and phase: Unknown; Phase 3

Conditions: Inflammation; Pterygium

Treatments: Drug: Intralesional injection of bevacizumab; Drug: Topical antihistamine and vasoconstrictor

Study type: Interventional

Funder types: Other

Identifiers

NCT01380678

KKU-1007

Details and patient eligibility

About

The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.

Full description

To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment

Enrollment: 206 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• primary pterygium

Exclusion criteria

• previous ocular surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

206 participants in 2 patient groups

bevacizumab

Active Comparator group

Description:

intralesional bevacizumab injection

Treatment:

Drug: Intralesional injection of bevacizumab

Topical antihistamine and vasoconstrictor

Active Comparator group

Description:

combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%

Treatment:

Drug: Topical antihistamine and vasoconstrictor